[{"orgOrder":0,"company":"Immunolight","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Methoxsalen","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Immunolight","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Immunolight \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunolight \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Immunolight

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : The heart of the X-PACT system is 8-MOP (also known as 8-methoxypsoralen or methoxsalen) which has been successfully used for decades in the treatment of autoimmune disease, skin disorders and certain skin and blood cancers.

                          Brand Name : X-PACT System

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 16, 2021

                          Lead Product(s) : Methoxsalen

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank